# Stimulant Use Disorders: Developing Drugs for Treatment - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/stimulant-use-disorders-developing-drugs-for-treatment/396da81b-e089-444c-9781-b40a43a1cff2

> FDA guidance document: Stimulant Use Disorders: Developing Drugs for Treatment. Issue date: October 05, 2023. Get complete insights and analysis.

---

## Details

- Title: Stimulant Use Disorders: Developing Drugs for Treatment
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-10-05
- Comment Close Date: 2023-12-04
- Last Changed: 2023-10-05
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-1848">FDA-2023-D-1848</a>

## Related Documents

- [Erosive Esophagitis: Developing Drugs for Treatment: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/erosive-esophagitis-developing-drugs-for-treatment-draft-guidance-for-industry/db47ebb5-eadc-4f7b-a236-ac6b016c3ec7)
- [Erosive Esophagitis: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/erosive-esophagitis-developing-drugs-for-treatment/985e94e3-4616-49e9-822e-0854256bb10e)
- [Migraine:  Developing Drugs for Preventive Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/migraine-developing-drugs-for-preventive-treatment/cd739d7c-f8ed-4a37-b16f-d6f3b9550a94)